Literature DB >> 20140139

A Human Monoclonal Antibody Against Tumor Necrosis Factor-alpha.

.   

Abstract

Entities:  

Year:  2009        PMID： 20140139      PMCID： PMC2810175     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  30 in total

1.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Authors:  Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06-15

2.  Epidemiology of psoriatic arthritis in the population of the United States.

Authors:  Joel M Gelfand; Dafna D Gladman; Philip J Mease; Nana Smith; David J Margolis; Tamar Nijsten; Robert S Stern; Steven R Feldman; Tara Rolstad
Journal:  J Am Acad Dermatol       Date:  2005-10       Impact factor: 11.527

3.  Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

Authors:  E William St Clair; Désirée M F M van der Heijde; Josef S Smolen; Ravinder N Maini; Joan M Bathon; Paul Emery; Edward Keystone; Michael Schiff; Joachim R Kalden; Ben Wang; Kimberly Dewoody; Roberta Weiss; Daniel Baker
Journal:  Arthritis Rheum       Date:  2004-11

4.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Authors:  Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green
Journal:  Arthritis Rheum       Date:  2006-01

Review 5.  Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis.

Authors:  John C Davis
Journal:  Semin Arthritis Rheum       Date:  2005-02       Impact factor: 5.532

6.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

Authors:  Charles G Helmick; David T Felson; Reva C Lawrence; Sherine Gabriel; Rosemarie Hirsch; C Kent Kwoh; Matthew H Liang; Hilal Maradit Kremers; Maureen D Mayes; Peter A Merkel; Stanley R Pillemer; John D Reveille; John H Stone
Journal:  Arthritis Rheum       Date:  2008-01

7.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.

Authors:  Edward C Keystone; Arthur F Kavanaugh; John T Sharp; Hyman Tannenbaum; Ye Hua; Leah S Teoh; Steven A Fischkoff; Elliot K Chartash
Journal:  Arthritis Rheum       Date:  2004-05

8.  Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.

Authors:  Paul Emery; Roy M Fleischmann; Larry W Moreland; Elizabeth C Hsia; Ingrid Strusberg; Patrick Durez; Peter Nash; Eric Jason B Amante; Melvin Churchill; Won Park; Bernardo Antonio Pons-Estel; Mittie K Doyle; Sudha Visvanathan; Weichun Xu; Mahboob U Rahman
Journal:  Arthritis Rheum       Date:  2009-08

9.  Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.

Authors:  Arthur Kavanaugh; Iain McInnes; Philip Mease; Gerald G Krueger; Dafna Gladman; Juan Gomez-Reino; Kim Papp; Julie Zrubek; Surekha Mudivarthy; Michael Mack; Sudha Visvanathan; Anna Beutler
Journal:  Arthritis Rheum       Date:  2009-04

10.  Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.

Authors:  J Smolen; R B Landewé; P Mease; J Brzezicki; D Mason; K Luijtens; R F van Vollenhoven; A Kavanaugh; M Schiff; G R Burmester; V Strand; J Vencovsky; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2008-11-17       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.